Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

06/10/16 - by

An ultrasound examination (photo: Jan Chlebik/the ICR)

An ultrasound examination (photo: Jan Chlebik/the ICR)

Ultrasound is found in hospitals and doctors’ surgeries all over the world, and many of us will have been scanned at some point in our lives, even if it was before we were born.

At its simplest, medical ultrasound uses high-frequency sound waves to create images of areas inside of the body. Now, more sophisticated applications are being tested in cancer.

During the course of their treatment, nearly half of all cancer patients receive radiotherapy, which directs high-energy beams of radiation at tumours inside the body to destroy cancer cells.

Radiotherapy is carefully planned to avoid damaging healthy tissue as much as possible, but tumours can move or change shape during treatment, so some damage to surrounding tissues is often inevitable.

We’ve talked about ultrasound in the past, discussing how high-intensity beams of ultrasound can be used to blast tumours as an exciting new way to treat cancer.

But ultrasound can also improve how we deliver and monitor radiotherapy by providing accurate measurements of the position of the tumour.

Ultrasound (photo: Dr Emma Harris)

Detecting tissue movement using ultrasound (image: Dr Emma Harris, image from Emma Harris et al, Physics in Medicine and Biology 2016)

Dr Emma Harris is Leader of the Imaging for Radiotherapy Adaptation Team at The Institute of Cancer Research, London, and she’s involved with two clinical trials which are using ultrasound to monitor tumour motion in patients with cervical cancer and prostate cancer.

At the moment, we rely on markers implanted into the prostate to guide prostate therapy, but these markers cannot easily be used to monitor the motion of the prostate during treatment. For patients with cervical cancer, we use cone-beam CT, which does not always give us a good image of the cervix and uterus.

Controlling the 'shape' of radiation

Dr Harris is using ultrasound image guidance for patients with prostate cancer, to locate the prostate and monitor its position during radiotherapy. She’s comparing how ultrasound measures up to other techniques to see if it can improve radiotherapy.

She recently teamed up with Professor Uwe Oeflke’s lab, and together they were the first to demonstrate that ultrasound can be used to control machines used to deliver radiotherapy. These machines use multi-leaf collimators, which are adjustable metallic ‘leaves’ that control the shape of the radiation beam, and by adding feedback about prostate position from ultrasound, multi-leaf collimators can adjust the radiation beam to follow the motion of the prostate. They have shown that this can improve the accuracy with which radiotherapy is delivered.

And ultrasound may be able to do more than just help track cancer. Different tumours, or even, different regions within tumours can respond differently to radiation depending on their biology, and ultrasound may be able to pick out this variation to help doctors make better decisions about the best course of treatment for a patient.

Tracking treatment response

In a recent review paper, Dr Harris explored the potential of ultrasound to measure treatment response. For example, tumour hypoxia occurs when cancer cells are deprived of oxygen, and it’s known to lead to cells that are more resistant to radiotherapy. Dr Harris believes that ultrasound may be able to measure tumour response and identify these regions at early stages of therapy, which may improve outcomes for patients receiving radiotherapy.

Ultrasound has the advantage of being an affordable technology, which can be integrated with any standard radiotherapy treatment machine, allowing doctors to scan patients at multiple times during their therapy.

From planning radiotherapy and guiding treatment as it happens, to assessing how tumours respond to therapy, ultrasound is helping doctors see cancer in a whole new way.